Received Jun 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
no adverse event; Inbound call from pharmacist calling to inquire about GARDASIL-9 dosing schedule. Caller states that patient received her first dose of GARDASIL-9 a year prior on 13-JUN-2024 and received her second dose in 02-JUN-2025. Pharmacist states that patie; This spontaneous report was received from a pharmacist and refers to a 45-year-old female patient. Her concurrent conditions, medical history and concomitant therapies were not provided. On 13-JUN-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) (dose, route of administration, lot # and expiration date were not provided) for prophylaxis. On 02-JUN-2025, she was administered the second dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) (dose, route of administration, lot # and expiration date were not provided) for prophylaxis (Inappropriate schedule of product administration). No adverse events were reported. Lot # is being requested and will be submitted if received.